Westfield Capital Management
IDIX

Westfield Capital Management’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Westfield Capital Management’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,748,504
Closed -$9.07M – 381
2013
Q3 		$9.07M Sell
1,748,504
-101,530
-5% -$445K 0.06% 238
2013
Q2 		$6.68M Buy
+1,850,034
New +$7.57M 0.05% 250

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Westfield Capital Management's IDIX Position: Q4 2013 in Review

Westfield Capital Management sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q4 2013, closing a stake of 1,748,504 shares — an estimated $9.07M sold.

Westfield Capital Management first reported a position in IDIX in Q2 2013 and held it in 2 quarters. The position peaked at $9.07M in Q3 2013. 88 funds tracked by Wall St. Rank hold IDIX as of Q4 2013.

  • Westfield Capital Management reported no remaining IDENIX PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Westfield Capital Management sold 1,748,504 IDENIX PHARMACEUTICALS INC shares in Q4 2013, an estimated $9.07M.
  • Westfield Capital Management first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and held it in 2 quarters.
  • Westfield Capital Management's IDENIX PHARMACEUTICALS INC position peaked at $9.07M in Q3 2013.
  • 88 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q4 2013.

Based on Westfield Capital Management's 13F filing for Q4 2013, filed 7 Feb 2014.